» Articles » PMID: 10380879

Stage-specific Changes in SR Splicing Factors and Alternative Splicing in Mammary Tumorigenesis

Overview
Journal Oncogene
Date 1999 Jun 25
PMID 10380879
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Using a mouse model of mammary gland development and tumorigenesis we examined changes in both alternative splicing and splicing factors in multiple stages of mammary cancer. The emphasis was on the SR family of splicing factors known to influence alternative splicing in a wide variety of genes, and on alternative splicing of the pre-mRNA encoding CD44, for which alternative splicing has been implicated as important in a number of human cancers, including breast cancer. We observed step-wise increases in expression of individual SR proteins and alternative splicing of CD44 mRNA during mammary gland tumorigenesis. Individual preneoplasias differed as to their expression patterns for SR proteins, often expressing only a sub-set of the family. In contrast, tumors demonstrated a complex pattern of SR expression. Little difference was observed between neoplasias and their metastases. Alternative splicing of CD44 also changed through the disease paradigm such that tumors produced RNA containing a mixture of variable exons, whereas preneoplasias exhibited a more restricted exon inclusion pattern. In contrast, other standard splicing factors changed little in either concentration or splicing pattern in the same cells. These data suggest alterations in relative concentrations of specific splicing factors during early preneoplasia that become more pronounced during tumor formation. Given the ability of SR proteins to affect alternative processing decisions, our results suggest that a number of pre-mRNAs may undergo changes in alternative splicing during the early and intermediate stages of mammary cancer.

Citing Articles

Oncogenic SRSF3 in health and diseases.

Jia R, Zheng Z Int J Biol Sci. 2023; 19(10):3057-3076.

PMID: 37416784 PMC: 10321290. DOI: 10.7150/ijbs.83368.


In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target.

Vujovic A, de Rooij L, Keyvani Chahi A, Chen H, Yee B, Loganathan S Blood Cancer Discov. 2023; 4(3):180-207.

PMID: 36763002 PMC: 10150294. DOI: 10.1158/2643-3230.BCD-22-0086.


Biological function and molecular mechanism of SRSF3 in cancer and beyond.

Xiong J, Chen Y, Wang W, Sun J Oncol Lett. 2021; 23(1):21.

PMID: 34858525 PMC: 8617561. DOI: 10.3892/ol.2021.13139.


ATP5A1 Participates in Transcriptional and Posttranscriptional Regulation of Cancer-Associated Genes by Modulating Their Expression and Alternative Splicing Profiles in HeLa Cells.

Song Ba Y, Wang Ma F, Wei Ma Y, Chen Ba D, Deng Ba G Technol Cancer Res Treat. 2021; 20:15330338211039126.

PMID: 34520292 PMC: 8445539. DOI: 10.1177/15330338211039126.


Differential Functions of Splicing Factors in Mammary Transformation and Breast Cancer Metastasis.

Park S, Brugiolo M, Akerman M, Das S, Urbanski L, Geier A Cell Rep. 2019; 29(9):2672-2688.e7.

PMID: 31775037 PMC: 6936330. DOI: 10.1016/j.celrep.2019.10.110.